{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T02:09:24Z","timestamp":1793239764801,"version":"4.5.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:00:00Z","timestamp":1771200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["2024-03471"],"award-info":[{"award-number":["2024-03471"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006313","name":"Barncancerfonden","doi-asserted-by":"publisher","award":["PR2021-0061"],"award-info":[{"award-number":["PR2021-0061"]}],"id":[{"id":"10.13039\/501100006313","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002794","name":"Cancerfonden","doi-asserted-by":"publisher","award":["23 2698 Pj H"],"award-info":[{"award-number":["23 2698 Pj H"]}],"id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Lokon Pharma AB sponsored the clinical trial"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    This phase I\/II study evaluated the capacity of tumor microenvironment (TME) gene engineering by intratumoral injection of a viral vector encoding a designed CD40L and 4-1BBL combined with intravenous atezolizumab (anti-PD-L1 antibody) to induce immune activation in 24 patients with stage IV malignant melanoma refractory to PD-1 inhibition. Primary objective was tolerability. Tumor response, pharmacokinetics, and biomarker evaluations were secondary. Treatment was well-tolerated in both dose cohorts (1\u00d710\n                    <jats:sup>11<\/jats:sup>\n                    and 5\u00d710\n                    <jats:sup>11<\/jats:sup>\n                    viral particles). Th1 immune biomarkers was increased in the TME (NanoString) as well as in blood (Olink). In long-term survivors, we observed increased markers for T cell fitness and for the immunoproteasome. The overall response rate was 17% accordingly to RECIST 1.1 and disease control was noted in 54%. Forty-six percent of patients were still alive two years post enrollment. The lower dose showed very encouraging results with a median progression-free survival of 9.7 months and median overall survival of 26.3 months (post-hoc analyses). In conclusion, TME gene engineering may have re-sensitized refractory patients to checkpoint treatment or acted alone to control tumor growth. The small sample size and single arm design limits effect interpretation but the data shows promise for continued clinical investigation. Study registration: NCT04123470.\n                  <\/jats:p>","DOI":"10.1038\/s41467-026-69629-0","type":"journal-article","created":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T15:43:17Z","timestamp":1771256597000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["LOAd703-induced tumor microenvironment gene engineering in combination with atezolizumab in metastatic malignant melanoma: a phase I\/II trial"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8238-4655","authenticated-orcid":false,"given":"O.","family":"Hamid","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-6053-3392","authenticated-orcid":false,"given":"V.","family":"Ekstr\u00f6m-Ryd\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2253-2206","authenticated-orcid":false,"given":"I.","family":"Mehmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3341-8652","authenticated-orcid":false,"given":"D.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4127-3147","authenticated-orcid":false,"given":"M.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7874-8084","authenticated-orcid":false,"given":"S.","family":"Alsaqal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2107-7512","authenticated-orcid":false,"given":"S.","family":"Irenaeus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Nordstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"LC","family":"Sandin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4412-5695","authenticated-orcid":false,"given":"H.","family":"Grauers Wiktorin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2170-0682","authenticated-orcid":false,"given":"T.","family":"L\u00f6vgren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Eriksson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Leja-Jarblad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8583-6138","authenticated-orcid":false,"given":"A.","family":"Loskog","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4949-3267","authenticated-orcid":false,"given":"GJ","family":"Ullenhag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,16]]},"reference":[{"key":"69629_CR1","doi-asserted-by":"crossref","unstructured":"Saginala, K., Barsouk, A., Aluru, J. S., Rawla, P. & Barsouk, A. Epidemiology of Melanoma. Med. Sci. 9, 63 (2021).","DOI":"10.3390\/medsci9040063"},{"key":"69629_CR2","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1038\/s41590-022-01141-1","volume":"23","author":"AC Huang","year":"2022","unstructured":"Huang, A. C. & Zappasodi, R. A decade of checkpoint blockade immunotherapy in melanoma: understanding the molecular basis for immune sensitivity and resistance. Nat. Immunol. 23, 660\u2013670 (2022).","journal-title":"Nat. Immunol."},{"key":"69629_CR3","unstructured":"Food and Drug Administration. Summary Review for Regulatory Action, Application Number 202429Orig1s000. Vol. 2024 (Center for Drug Evaluation and Research, 2011)."},{"key":"69629_CR4","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","volume":"381","author":"J Larkin","year":"2019","unstructured":"Larkin, J. et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N. Engl. J. Med. 381, 1535\u20131546 (2019).","journal-title":"N. Engl. J. Med."},{"key":"69629_CR5","doi-asserted-by":"publisher","first-page":"3917","DOI":"10.1158\/1078-0432.CCR-21-1804","volume":"28","author":"MM Gubin","year":"2022","unstructured":"Gubin, M. M. & Vesely, M. D. Cancer immunoediting in the era of immuno-oncology. Clin. Cancer Res. 28, 3917\u20133928 (2022).","journal-title":"Clin. Cancer Res."},{"key":"69629_CR6","doi-asserted-by":"publisher","first-page":"2346","DOI":"10.1200\/JCO.2005.00.240","volume":"23","author":"ME Dudley","year":"2005","unstructured":"Dudley, M. E. et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J. Clin. Oncol. 23, 2346\u20132357 (2005).","journal-title":"J. Clin. Oncol."},{"key":"69629_CR7","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s40291-024-00708-y","volume":"28","author":"SJ Keam","year":"2024","unstructured":"Keam, S. J. Lifileucel: first approval. Mol. Diagn. Ther. 28, 339\u2013344 (2024).","journal-title":"Mol. Diagn. Ther."},{"key":"69629_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.632581","volume":"12","author":"S Schreiber","year":"2021","unstructured":"Schreiber, S. et al. Metabolic interdependency of Th2 cell-mediated type 2 immunity and the tumor microenvironment. Front. Immunol. 12, 632581 (2021).","journal-title":"Front. Immunol."},{"key":"69629_CR9","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1146\/annurev-med-062518-045435","volume":"71","author":"RH Vonderheide","year":"2020","unstructured":"Vonderheide, R. H. CD40 agonist antibodies in cancer immunotherapy. Annu. Rev. Med. 71, 47\u201358 (2020).","journal-title":"Annu. Rev. Med."},{"key":"69629_CR10","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1038\/s41417-020-0176-9","volume":"27","author":"J Wenthe","year":"2020","unstructured":"Wenthe, J. et al. Immunostimulatory oncolytic virotherapy for multiple myeloma targeting 4-1BB and\/or CD40. Cancer Gene Ther. 27, 948\u2013959 (2020).","journal-title":"Cancer Gene Ther."},{"key":"69629_CR11","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.omto.2022.01.003","volume":"24","author":"J Wenthe","year":"2022","unstructured":"Wenthe, J. et al. Immune priming using DC- and T cell-targeting gene therapy sensitizes both treated and distant B16 tumors to checkpoint inhibition. Mol. Ther. Oncolytics 24, 429\u2013442 (2022).","journal-title":"Mol. Ther. Oncolytics"},{"key":"69629_CR12","doi-asserted-by":"publisher","first-page":"5846","DOI":"10.1158\/1078-0432.CCR-17-0285","volume":"23","author":"E Eriksson","year":"2017","unstructured":"Eriksson, E. et al. Shaping the tumor stroma and sparking immune activation by CD40 and 4-1BB signaling induced by an armed oncolytic virus. Clin. Cancer Res. 23, 5846\u20135857 (2017).","journal-title":"Clin. Cancer Res."},{"key":"69629_CR13","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1038\/s41423-021-00734-4","volume":"19","author":"TNJ Bullock","year":"2022","unstructured":"Bullock, T. N. J. CD40 stimulation as a molecular adjuvant for cancer vaccines and other immunotherapies. Cell Mol. Immunol. 19, 14\u201322 (2022).","journal-title":"Cell Mol. Immunol."},{"key":"69629_CR14","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/cgt.2014.2","volume":"21","author":"L Liljenfeldt","year":"2014","unstructured":"Liljenfeldt, L., Dieterich, L. C., Dimberg, A., Mangsbo, S. M. & Loskog, A. S. CD40L gene therapy tilts the myeloid cell profile and promotes infiltration of activated T lymphocytes. Cancer Gene Ther. 21, 95\u2013102 (2014).","journal-title":"Cancer Gene Ther."},{"key":"69629_CR15","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/gt.2016.80","volume":"24","author":"E Eriksson","year":"2017","unstructured":"Eriksson, E. et al. Activation of myeloid and endothelial cells by CD40L gene therapy supports T-cell expansion and migration into the tumor microenvironment. Gene Ther. 24, 92\u2013103 (2017).","journal-title":"Gene Ther."},{"key":"69629_CR16","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/cmi.2008.15","volume":"5","author":"Y Xia","year":"2008","unstructured":"Xia, Y. et al. Distinct effect of CD40 and TNF-signaling on the chemokine\/chemokine receptor expression and function of the human monocyte-derived dendritic cells. Cell Mol. Immunol. 5, 121\u2013131 (2008).","journal-title":"Cell Mol. Immunol."},{"key":"69629_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-023-04374-2","volume":"21","author":"J Wenthe","year":"2023","unstructured":"Wenthe, J. et al. Immunostimulatory gene therapy targeting CD40, 4-1BB and IL-2R activates DCs and stimulates antigen-specific T-cell and NK-cell responses in melanoma models. J. Transl. Med. 21, 506 (2023).","journal-title":"J. Transl. Med."},{"key":"69629_CR18","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/s12276-023-01136-4","volume":"56","author":"R Singh","year":"2024","unstructured":"Singh, R., Kim, Y. H., Lee, S. J., Eom, H. S. & Choi, B. K. 4-1BB immunotherapy: advances and hurdles. Exp. Mol. Med. 56, 32\u201339 (2024).","journal-title":"Exp. Mol. Med."},{"key":"69629_CR19","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.18162","volume":"28","author":"S Naseri","year":"2024","unstructured":"Naseri, S. et al. CD40 stimulation via CD40 ligand enhances adenovirus-mediated tumour immunogenicity including \u2018find-me\u2019, \u2018eat-me\u2019, and \u2018kill-me\u2019 signalling. J. Cell Mol. Med. 28, e18162 (2024).","journal-title":"J. Cell Mol. Med."},{"key":"69629_CR20","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/S1470-2045(24)00079-2","volume":"25","author":"BL Musher","year":"2024","unstructured":"Musher, B. L. et al. LOAd703, an oncolytic virus-based immunostimulatory gene therapy, combined with chemotherapy for unresectable or metastatic pancreatic cancer (LOKON001): results from arm 1 of a non-randomised, single-centre, phase 1\/2 study. Lancet Oncol. 25, 488\u2013500 (2024).","journal-title":"Lancet Oncol."},{"key":"69629_CR21","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1111\/pcmr.13156","volume":"37","author":"V Ryd\u00e9n","year":"2024","unstructured":"Ryd\u00e9n, V. et al. The role of dacarbazine and temozolomide therapy after treatment with immune checkpoint inhibitors in malignant melanoma patients: a case series and meta-analysis. Pigment Cell Melanoma Res. 37, 352\u2013362 (2024).","journal-title":"Pigment Cell Melanoma Res."},{"key":"69629_CR22","doi-asserted-by":"crossref","unstructured":"Chesney, J. et al. Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study. J. Immunother. Cancer 10, e005755 (2022).","DOI":"10.1136\/jitc-2022-005755"},{"key":"69629_CR23","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1056\/NEJMoa2210233","volume":"387","author":"MW Rohaan","year":"2022","unstructured":"Rohaan, M. W. et al. Tumor-infiltrating lymphocyte therapy or ipilimumab in advanced melanoma. N. Engl. J. Med. 387, 2113\u20132125 (2022).","journal-title":"N. Engl. J. Med."},{"key":"69629_CR24","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1111\/cts.13127","volume":"15","author":"B Wu","year":"2022","unstructured":"Wu, B. et al. Evaluation of atezolizumab immunogenicity: clinical pharmacology (part 1). Clin. Transl. Sci. 15, 130\u2013140 (2022).","journal-title":"Clin. Transl. Sci."},{"key":"69629_CR25","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","volume":"33","author":"RH Andtbacka","year":"2015","unstructured":"Andtbacka, R. H. et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J. Clin. Oncol. 33, 2780\u20132788 (2015).","journal-title":"J. Clin. Oncol."},{"key":"69629_CR26","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/S1470-2045(20)30540-4","volume":"22","author":"SA Boorjian","year":"2021","unstructured":"Boorjian, S. A. et al. Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial. Lancet Oncol. 22, 107\u2013117 (2021).","journal-title":"Lancet Oncol."},{"key":"69629_CR27","doi-asserted-by":"crossref","unstructured":"Hamid, O. et al. First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors. J. Immunother. Cancer 10, e005471 (2022).","DOI":"10.1136\/jitc-2022-005471"},{"key":"69629_CR28","doi-asserted-by":"publisher","first-page":"968360","DOI":"10.3389\/fonc.2022.968360","volume":"12","author":"AMJ Kim","year":"2022","unstructured":"Kim, A. M. J., Nemeth, M. R. & Lim, S. O. 4-1BB: a promising target for cancer immunotherapy. Front. Oncol. 12, 968360 (2022).","journal-title":"Front. Oncol."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-69629-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-69629-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-69629-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T05:03:30Z","timestamp":1771391010000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-69629-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,16]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["69629"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-69629-0","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,16]]},"assertion":[{"value":"17 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Drs. Loskog, Eriksson, Sandin, Leja-Jarblad, and Ms. Norstr\u00f6m are employees of Lokon Pharma AB. Dr. Loskog is a board member of Lokon Pharma AB and an alternate board member of Nexttobe AB. Further, she is the inventor of a patent owned by Lokon Pharma AB in regard to LOAd703 and holds a research grant together with Dr. L\u00f6vgren from Lokon Pharma AB. Other authors do not report any conflicts of interest in regard to the data presented in the paper.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1760"}}